Percutaneous Robotic Navigation Microwave Ablation Versus CT-guided Microwave Ablation in the Treatment of Pulmonary Nodules With Ground-glass Opacity
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Robot, CT scan.
- Who it may be relevant to
- Registry conditions: Pulmonary Nodules, Ground-glass Opacity. Basic parameters: 18 years — 85 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Percutaneous Robotic Navigation Microwave Ablation Versus CT-guided Microwave Ablation in the Treatment of Pulmonary Nodules With Ground-glass Opacity: A Prospective Randomized Controlled Trial
Overview
1. To compare the precision of robot-guided microwave ablation and CT-guided microwave ablation in the treatment of ground-glass nodules. 2. To evaluate the safety of robot-assisted microwave ablation and CT-guided microwave ablation in the treatment of ground-glass nodules. 3. Explore the application potential of robot navigation microwave ablation technology in the treatment of pulmonary nodules.
Interventions
- Procedure Robot
Microwave ablation guided by Robot or CT - Procedure CT scan
CT
Primary outcome measures
- Accuracy of puncture [Time frame: 24 month]
Eligibility criteria
Inclusion criteria
- Aged 18 to 85 years
- Nodules measuring 3-30mm with ground-glass opacities constituting ≥75% of the lesion
- Preoperative clinical evaluation confirming no hilar or mediastinal lymph node metastasis and no distant metastasis
- Patients diagnosed as stage IA primary peripheral lung cancer according to the UICC 8th TNM staging system, and with one of the following conditions:
(i) cannot undergo surgical resection due to poor cardiopulmonary function or advanced age (ii) refusing or unwilling to undergo surgical resection (iii) with newly developed or residual pulmonary nodules after early-stage primary lung cancer surgery (iv) with unilateral lung disease who cannot undergo unilateral surgical resection (v)with multiple primary lung cancers unsuitable for surgical resection
- Preoperative ECOG physical status score is 0/1
- ASA score is I-III
- Patients voluntarily participate in this study and sign the informed consent form
Exclusion criteria
- Smoking cessation duration <2 weeks
- Lesions adjacent to pulmonary artery-vein main trunks
- Lesions near the hilum or adjacent to lobar bronchi
- Pregnancy or lactation status
- Severe mental disorders
- History of other malignancies within 5 years
- Unstable angina or myocardial infarction within 6 months with coronary angiography showing severe stenosis of major coronary branches
- Cerebral infarction or hemorrhage within 6 months
- Continuous systemic corticosteroid therapy within 1 month
- Patients or their authorized persons who do not wish to comply with the study protocol
- Patients with other investigator-assessed ineligibility for the trial
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07389889 · union TC1